Explore the Effect of Bitter Melon Peptides on Glycemic Control and Metabolic Indicators in Diabetic Patients

Last updated: May 6, 2025
Sponsor: Changhua Christian Hospital
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Diabetic Gastroparesis

Diabetic Kidney Disease

Diabetic Foot Ulcers

Treatment

bitter melon peptides

Clinical Study ID

NCT06970834
CCH IRB 250121
  • Ages 20-80
  • All Genders

Study Summary

The goal of this clinical trial is to learn the potential of bitter melon peptides in stabilizing blood glucose in diabetic adults. It will also learn about the effects of bitter melon peptides on metabolic parameters. The main questions it aims to answer are:

  • the regulatory effects of bitter melon peptides on glycemic variability

  • impact on glycemic and metabolic indicators Researchers will compare bitter melon peptides to a placebo (a look-alike capsule that contains Microcrystalline Cellulose) to see if bitter melon peptides works to stabilizing blood glucose.

Participants will:

  • Take bitter melon peptides or a placebo every day for 12 weeks

  • Visit the clinic on day 0, day 7, day 28 and day 84 for checkups and tests

  • Glucose levels were monitored continuously by CGMs in the first 7 days and fasting blood samples were drawn at first visit (day0), third visit (day 28) and fourth visits (day 84)

Eligibility Criteria

Inclusion

Inclusion Criteria:Participants were diagnosed with type 2 DM based on criteria recommended by the American Diabetes Association and required to have fasting plasma glucose of ≥126 mg/dl or an HbA1c of

≥ 6.5%, as measured on two separate occasions

Exclusion

Exclusion Criteria:cancer, active liver disease, current pregnancy , acute illness and autoimmune thyroid disease.

Study Design

Total Participants: 160
Treatment Group(s): 1
Primary Treatment: bitter melon peptides
Phase:
Study Start date:
May 27, 2025
Estimated Completion Date:
March 26, 2026